However, the results from our clinical study make it clear that Msx2 is a marker of good prognosis in human breast cancer, illustrating the principle that data obtained from in vitro laboratory work must be supplemented by clinical investigation to determine the real prognostic value of a biomarker. Here, MSX2 is linked to breast cancer.